Search for a trial

LUNAR: pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure

To test the efficacy and safety of TTFields, using the NovoTTF-200T System, concurrent with standard therapies for stage 4 NSCLC patients, followingprogression while on or after platinum based treatment

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This study has been transitioned to CTIS with ID 2023-509602-29-00 check the CTIS register for the current data. Primary objectives:- To assess the efficacy of durvalumab monotherapy compared to placebo in terms of PFS- To assess the efficacy of…

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

The primary objective is to compare the antitumor activity of LDK378 versus reference chemotherapy

Chemotherapy in KRAS mutated chemotherapy naive non-small cell lung cancer patients: a phase III study comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22

To compare two (standard) treatment regimens in patients with KRAS mutated advanced stage NSCLC as first line treatment.

Clinical Performance Study Plan (CPSP) for the use of GenDx CDx Tedopi for subject enrollment on to the OSE Immunotherapeutics Phase 3 trial (OSE2101C302) of OSE2101 versus docetaxel in HLA-A*02 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ARTEMIA)

This clinical performance study/clinical investigation will evaluate the safety and effectiveness of GenDx CDx Tedopi in identifying HLA-A*02 status in metastatic NSCLC subjects who may be eligible for treatment with OSE2101.

Cardiac changes after stereotactic radiotherapy for early stage NSCLC cancer or lung metastasis - HALO

We aim to optimize the radiation treatment of early stage lung cancer patients. Cardiac sparing is possible, but it comes at the cost of an increased mean lung dose. Without proof of cardiac toxicity, cardiac sparing will not be (routinely) applied…

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER.

This study has been transitioned to CTIS with ID 2023-505981-26-00 check the CTIS register for the current data. Primary Efficacy ObjectiveThe primary efficacy objective of the study is as follows:• To evaluate the efficacy of 16 cycles of…

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Given the limited effectiveness of available EGFR TKIs in patients with NSCLC with EGFR exon 20 insertion mutations, this subset patient population is routinely treated with chemotherapy, similar to patients with no driver mutations (ie, WT EGFR).…

A Phase 3, Randomized, Double blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2022-502658-15-00 check the CTIS register for the current data. Primary Objective• To compare the event-free survival (EFS) by blinded independent central review (BICR) in Arm A (vs Arm B…

A Phase 3, randomized, open label study of lorlatinib (PF 06463922) monotherapy versus crizotinib monotherapy in the first line treatment of patients with advanced ALK positive non small cell lung cancer

This study has been transitioned to CTIS with ID 2023-509169-19-00 check the CTIS register for the current data. To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival…

Pembrolizumab alone versus pembrolizumab-chemotherapy in first line NSCLC

This study has been transitioned to CTIS with ID 2024-516581-11-00 check the CTIS register for the current data. Primary Objective:- to assess the effect of chemotherapy given concurrently with pembrolizumab on overall response rate (ORR) in NSCLC…

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER.

The objective for this study is to evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in patients with untreated extensive-stage small cell lung cancer (ES-SCLC)…

Dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy trial number 1

To investigate the non-inferiority of a reduced dose and to develop biomarkers for early treatment response.

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD 1)

The research hypothesis for this study is that concurrent durvalumab plus SoC chemotherapy will be more effective than placebo plus SoC chemotherapy for the treatment of MRD+ patients who have undergone complete resection of stage II-III NSCLC when…

Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer With or Without Actionable Genomic Alterations

This study has been transitioned to CTIS with ID 2023-509865-19-00 check the CTIS register for the current data. To compare the efficacy of DS-1062a with that of docetaxel, as measured by PFS and OS, for subjects with NSCLC with or without…

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

This study has been transitioned to CTIS with ID 2022-502977-41-00 check the CTIS register for the current data. Primary ObjectiveTo assess the efficacy of furmonertinib compared to platinum-based chemotherapy using progression-free survival (PFS)…

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

This study has been transitioned to CTIS with ID 2023-509429-37-00 check the CTIS register for the current data. In this study, we want to learn more about the effect and safety of Ceralasertib plus Durvalumab on the inhibition of tumour growth, and…

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-503517-30-00 check the CTIS register for the current data. Primary objectivesTo compare overall survival for MK-7684A in combination with the background therapy of etoposide/platinum followed by…

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-505749-14-00 check the CTIS register for the current data. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab…

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

This study has been transitioned to CTIS with ID 2023-509137-39-00 check the CTIS register for the current data. Primary/dualco-primary. To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (…